Cereno Scientific's shares of series B will continue to be traded under the ticker CRNO B with ISIN code SE0008241558. No new shares will be issued in connection with the admission to trading on Nasdaq First North. Trading with the warrants of series TO3 is intended to take place after registration of the completed rights issue with the Swedish Companies Registration Office, which the board of directors decided on April 20, 2023, with authorization from the annual general meeting on June 1, 2022. The Company's shareholders do not need to take any measures in connection with the list change.

Sten R. Sörensen, CEO of Cereno Scientific, said "We are thrilled about our listing on Nasdaq First North Growth Market, it is a pivotal milestone in our journey as a biotech company. This occasion not only validates the hard work and dedication of our exceptional team but also marks a significant step towards fulfilling our mission of advancing scientific innovation for the betterment of human health. We remain steadfast in our commitment to bringing innovative treatments for patients with common and rare cardiovascular disease and are excited about the opportunities that lie ahead as we continue to further develop our portfolio and create value for our stakeholders."

Advisors

Mangold Fondkommission AB is the Company's advisor in connection with the listing on Nasdaq First North and has been appointed as the Company's Certified Adviser. MAQS Advokatbyrå AB acts as legal advisor in connection with the listing on Nasdaq First North.

For further information, please contact:

Jonas Fogelberg, Interim CFO

Email: info@cerenoscientific.com

http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno Scientific to use their cutting-edge technology CardioMEMS HF System in the study. Cereno Scientific also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno Scientific is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.